Biochemistry Lab, Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Kavala University Campus, Democritus University of Thrace
Kavala, 65404, Greece
NCT Number: NCT07784166
This study aims to evaluate the in vivo antithrombotic and anti-inflammatory effects of extra virgin olive oil daily consumption at recommended doses for 1 month compared to similar consumption of classic table olive oil, in the blood plasma and platelets of healthy donors
This study is active but is not currently recruiting participants.
Notify MeAll sexes
Interventional
Not applicable
Kavala, 65404, Greece
Introduction: Thrombo-inflammatory manifestations are key pathophysiological mechanisms of cardiovascular diseases and are directly related to platelet activation and aggregation. Extra virgin olive oil, a key component of the Mediterranean diet, is rich in natural bioactives (e.g. unsaturated fatty acids, polar lipids, phenolic compounds, carotenoids and other pigments), which have been proposed to possess not only antioxidant activities, but mainly strong anti-inflammatory and antiplatelet properties, which contribute to the reduction of cardiovascular risk. However, to our knowledge, nutritional and biochemical evaluation of these properties through an in vivo intervention study has not been thoroughly conducted, especially for the cardioprotective benefits of consuming such an extra virgin olive oil against the main thrombo-inflammatory pathways, and compared to plain classic table olive oil.
Purpose: The purpose of this study was the qualitative characterization of a sample of extra virgin olive oil and the biochemical investigation of the effect of its daily consumption on platelet activation and on the mechanisms related to thrombo-inflammation compared to the effects observed by a similar consumption of classic table olive oil.
Materials and Methods: An in vivo dietary intervention study, randomised and single blinded (the volunteers did not know what type of olive oil they consumed) was performed on four arms:
In the 1st arm, 18 healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days.
In the 2nd arm, 18 other healthy volunteers consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days.
In the 3rd arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for another period of 28 days, in a crossover single blinded randomised design In the 4th arm, 9 healthy volunteers initially consumed the nutritionally recommended daily dose (30 mL) of plain classic table olive oil daily for 28 days and after a month washout period they then re-consumed the nutritionally recommended daily dose (30 mL) of extra virgin olive oil daily for another period of 28 days, in a crossover single blinded randomised design Blood samples were taken from all volunteers in all these 4 arms, on days 0 and 28 in each one of these interventions and platelet sensitization by various agonists was assessed just after blood sampling. Blood Plasma was stored at -20oC for further analysis Specifically the anti-inflammatory effects were expressed as the Effective Concentrations that induce 50% of platelet aggregation (EC50 values) by platelet-activating factor (PAF), the antithrombotic effects as the EC50 for Thrombin by using Thrombin Receptor Active Peptide (TRAP) and the antiplatelet effects as the EC50 values for ADP.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1st arm: 18 healthy volunteers consumed 30 mL of extra virgin olive oil (EVOO) daily for 28 days. Blood samples and biochemical assays were conducted just before (day 0) and after (day 28) this dietary intervention
Other names: Dietary Intervention, Extra virgin olive oil (EVOO) consumption, Single Blinded, Randomised
2nd arm, 18 other healthy volunteers consumed 30 mL of plain classic table olive oil (CTOO) daily for 28 days.
Other names: randomised, single blinded, plain classic table olive oil (CTOO) consumption, dietary intervention
3rd arm, 9 healthy volunteers initially consumed 30 mL of EVOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of CTOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions
Other names: single blinded, randomised, crossover, dietary intervention
4th arm, 9 healthy volunteers initially consumed 30 mL of CTOO daily for 28 days and after a washout period of 1 month they then re-consumed 30 mL of EVOO daily for 28 days, in a crossover single blinded randomized design with the 3rd arm. Blood sampling and Biochemical Assays were conducted just before (day 0) and just after (day 28) each of these interventions
Other names: Dietary Intervnention, Crossover, Single Blinded, Randomised
Time frame: Blood sampling and platelet sensitization by PAF is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
Time frame: Blood sampling and platelet sensitization by TRAP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
The antithrombotic effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Thrombin Pathway, measured in μM concentration of Thrombin Receptor Active Peptide (TRAP) that can cause 50% of platelet aggregation
Time frame: Blood sampling and platelet sensitization by ADP is assessed just before (day 0) and just after (day 28) of each intervention in platelets and plasma of blood samples from all volunteers in all these 4 arms
The antiplatelet effects of the intervention assessed in platelets and plasma of blood samples from all volunteers are expressed as the Effective Concentration that induce 50% of platelet aggregation (EC50 values) induced by the Adenosine 5' Diphosphate (ADP, measured in μM concentration of ADP that can cause 50% of platelet aggregation.
Democritus University of Thrace
Other
Study of the Anti-Inflammatory Health Benefits of "Argilos Extra Virgin Olive Oil" ("Healthy Argiloil")
Acronym: HealthAgriloil
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04010955
Acute Ischemic Stroke, Anticoagulant
Seoul, South Korea
View Trial DetailsNCT03437057
Antiplatelet, Female Urogenital Diseases
Clermont-Ferrand, France
View Trial DetailsNCT04237935
Antiplatelet
Boston, Massachusetts, United States
View Trial DetailsNCT04237922
Antiplatelet
Boston, Massachusetts, United States
View Trial Details